Boston Scientific Corporation (BSX)

FairStock Score: 59/100 — STEADY

Key Financials

Strengths

• Strong free cash flow generation of $3.2B annually demonstrates genuine earning power
• Diversified product portfolio across interventional medical specialties reduces concentration risk
• Low beta of 0.70 reflects defensive business model with recurring procedural revenue streams
• Healthy 12.71% net profit margins in latest quarter showing operational efficiency
• Solid financial structure with D/E ratio of 0.49 providing balance sheet flexibility

Concerns

• Valuation grossly excessive: P/E of 35.81 with Graham Number at $12.86 suggests 454% overvaluation
• Deteriorating financial quality reflected in Piotroski F-Score of 6/9 indicating weakening fundamentals
• Weak ROCE of 5.98% below cost of capital suggests capital allocation concerns and value destruction
• Extraordinarily high EV/EBITDA multiple of 99.87 leaves no margin of safety for disappointment

AI Analysis

Boston Scientific presents a paradox that troubles me. On one hand, we have a established medical device manufacturer with genuine competitive advantages—a diversified portfolio across interventional specialties, 59,000 employees generating $5.3B quarterly revenue, and respectable 12.71% net margins. The free cash flow of $3.2B demonstrates real earnings power. The low beta of 0.70 reflects a defensive healthcare business with recurring revenue from procedural demand. However, the valuation metrics are deeply concerning. At a P/E of 35.81 with our Graham Number suggesting intrinsic value near $12.86—a margin of safety of negative 454%—this stock is priced for perfection. The EV/EBITDA of 99.87 is extraordinarily expensive by any reasonable standard. What troubles me most is the Piotroski F-Score of 6/9, indicating deteriorating financial quality, coupled with a weak FCF yield of just 0.9%. The company's ROCE of 5.98% falls below its cost of capital, suggesting value destruction. While the Altman Z-Score of 3.78 indicates financial stability, I'm witnessing a mature business trading at growth stock multiples. The 52-week decline from $109.50 provides some comfort, yet the current $71.35 price still demands exceptional execution. I prefer to buy quality at fair prices, not fair quality at exorbitant prices. Boston Scientific is a competent operator in a growing sector, but the market has priced in decades of flawless execution.

Bull Case

Boston Scientific operates in structurally growing markets with aging populations driving procedural demand across cardiology and gastroenterology. Continued innovation in interventional devices, successful M&A integration, and geographic expansion could justify premium valuations if growth accelerates meaningfully above historical rates.

Bear Case

A mature market saturation, pricing pressure from healthcare consolidation, or execution missteps could render current valuations indefensible. Economic recession reducing elective procedures or competitive disruption would expose this stock's vulnerability given its premium pricing.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer